SMS [SM (sphingomyelin) synthase] is a class of enzymes that produces SM by transferring a phosphocholine moiety on to ceramide. PC (phosphatidylcholine) is believed to be the phosphocholine donor of the reaction with consequent production of DAG (diacylglycerol), an important bioactive lipid. In the present study, by modulating SMS1 and SMS2 expression, the role of these enzymes on the elusive regulation of DAG was investigated. Because we found that modulation of SMS1 or SMS2 did not affect total levels of endogenous DAG in resting cells, whereas they produce DAG in vitro, the possibility that SMSs could modulate subcellular pools of DAG, once acute activation of the enzymes is triggered, was investigated. Stimulation of SM synthesis was induced by either treatment with short-chain ceramide analogues or by increasing endogenous ceramide at the plasma membrane, and a fluorescently labelled conventional C1 domain [from PKC (protein kinase C)] enhanced in its DAG binding activity was used to probe subcellular pools of DAG in the cell. With this approach, we found, using confocal microscopy and subcellular fractionation, that modulation of SMS1 and, to a lesser extent, SMS2 affected the formation of DAG at the Golgi apparatus. Similarly, down-regulation of SMS1 and SMS2 reduced the localization of the DAG-binding protein PKD (protein kinase D) to the Golgi. These results provide direct evidence that both enzymes are capable of regulating the formation of DAG in cells, that this pool of DAG is biologically active, and for the first time directly implicate SMS1 and SMS2 as regulators of DAG-binding proteins in the Golgi apparatus.
INTRODUCTION
SMSs [SM (sphingomyelin) synthases] represent a class of enzymes involved in the synthesis of SM, an abundant phospholipid with an important structural role in the integrity of the plasma membrane. PC (phosphatidylcholine) is the proposed donor of the phosphocholine group that SMS transfers on to the primary hydroxy group of ceramide, generating DAG (diacylglycerol) as an additional product of the reaction [1] [2] [3] [4] [5] . Therefore it has been suggested that the biological importance of SMSs resides not only in the biosynthesis of SM but also in the regulation, in opposing directions, of the levels of ceramide, a bioactive molecule which often exerts a negative effect on cell proliferation, and DAG, a well-established signalling lipid [6] . Moreover, SMS activity, through the control of the levels of SM and ceramide, could also be involved in the functional modulation of plasma membrane lipid rafts [7, 8] .
In support of a role for SMS that goes beyond the housekeeping function of SM synthesis, positive regulation of its activity has been reported in association with conditions of enhanced proliferation and transformation, such as hepatic regeneration, astrocytes stimulated with bFGF (basic fibroblast growth factor), SV40 (simian virus 40)-transformed fibroblasts and hepatocellular carcinoma [6, 9, 10] . On the other hand, caspasedependent inhibition of SMS activity has been observed upon initiation of apoptosis by TNF (tumour necrosis factor) in Kym-1 rhabdomyosarcoma cells [11] or Fas cross-linking in Jurkat cells [12] that led to the hypothesis that inhibition of SMS could be a regulated process required for the full development of the apoptotic programme.
So far, only a few potential downstream targets for SMS have been identified. In particular, it has been proposed that activation of SM synthesis in response to growth initiation of Madin-Darby canine kidney cells by serum stimulation led to production of DAG which correlated with activation of PKC (protein kinase C) as measured by means of its membrane translocation [13] . Indirect evidence for a role of SMS in the regulation of PKC comes from studies in U937 human monocytic leukaemia cells where the use of a pharmacological inhibitor of SMS, D609, induced a significant accumulation of ceramide and a pronounced decrease in DAG levels, followed by cell death. Pretreatment with the PKC activator PMA or supplementation with a cell-permeable DAG analogue greatly attenuated D609-mediated cytotoxicity, bypassing the effect of SMS inhibition [14] . Additional studies from our group showed that active SM synthesis correlated with nuclear translocation and activation of NF-κB (nuclear factor κB) [15] , an important transcription factor often linked to survival pathways and inflammatory responses. Finally, DAG derived from sphingolipid metabolism has been potentially linked to translocation of PKD (protein kinase D) to the Golgi [16] .
Mammalian SMSs (namely, SMS1 and SMS2) have only been recently identified molecularly [17, 18] . Overall, no significant biochemical differences have been found between SMS1 and SMS2 [17] . On the other hand, a different cellular localization was shown for the two SMSs when expressed in HeLa human cervical carcinoma cells, where SMS1 localized in the Golgi and SMS2 in Golgi and plasma membrane [17] . This localization pattern is in agreement with earlier biochemical studies using fractionation techniques that reported the bulk of SMS activity in the Golgi and residual activity in other cellular compartments, including plasma membrane [3, 19] .
Studies conducted in mammalian models have confirmed the ability of both SMSs to regulate the levels of SM and ceramide in cells [7, 18, [20] [21] [22] [23] . On the other hand, no clear evidence for involvement of SMS1 or SMS2 in the regulation of DAG was provided. In fact, in these reports, down-regulation of either SMS did not induce significant changes in either PC or DAG levels.
In the present study, we employed both downregulation through siRNA (short interfering RNA) and up-regulation through overexpression to study the role of SMS1 and SMS2 in the regulation of DAG levels. After validation of the effects of our siRNA sequences and expression system, we show that both SMS1 and SMS2 are capable of regulating DAG formation at the Golgi and, by doing so, that they affect the localization of the DAG-binding protein PKD in this compartment.
EXPERIMENTAL

Materials
DMEM (Dulbecco's modified Eagle's medium) and RPMI 1640 medium, trypsin/EDTA and FBS (fetal bovine serum) were from Gibco/Invitrogen; anti-FLAG monoclonal antibodies were from Sigma and anti-(mouse IgG) was purchased from Santa Cruz Biotechnology; and anti-V5 monoclonal antibodies were purchased from Invitrogen. NBD [N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)]-C 6 -ceramide and NBD-C 6 -SM were purchased from Molecular Probes. [9,10- 3 H(n)]Palmitic acid and [methyl-3 H]choline chloride were purchased from American Radiolabeled Chemicals. All other lipids were purchased from Avanti Polar Lipids (Alabaster, AL, U.S.A.).
Cell culture
HeLa and SV40-transformed WI38 (fibroblast) cells were cultured in high glucose DMEM. The medium was supplemented with 10 % FBS and cells were grown at 37
• C in a humidified 5 % CO 2 incubator.
Down-regulation of SMS1 and SMS2
Down-regulation of SMS1 or SMS2 was achieved with siRNA oligonucleotides targeting SMS1 (CACACTATGGC-CAATCAGCAA) or SMS2 (AAGGCACCAAAAAGTACCCGG) synthesized by Qiagen, and by using Oligofectamine TM transfection reagent (Invitrogen). The non-specific All Star siRNA sequence (SCR; scrambled siRNA) was used as control (Qiagen). Typically, 0.2-0.23 × 10 6 HeLa cells from an exponentially growing culture not exceeding 20 passages were plated in 10-cm-diameter dishes. After approx. 24 h, cells were transfected with siRNA according to the manufacturer's instructions in a total of 6 ml of transfection mixture containing siRNA and Oligofectamine TM in Optimem medium. After 6 h of incubation, 6 ml of DMEM containing 20 % FBS was added to the plates.
DAG measurements
DAG levels were evaluated using the Escherichia coli DGK (diacylglycerol kinase) assay as described in [6] .
SMS assay
HeLa cells were collected and homogenized in ice-cold lysis buffer by 20 passages through a 28.5 gauge needle.
The lysis buffer contained 25 mM Tris/HCl (pH 7.4), 5 mM EDTA and 1 mM PMSF. Cell lysates were centrifuged at 300 g for 5 min at 4
• C, and the supernatant was used for measuring the enzymatic activity. Protein concentrations were determined using the Bio-Rad assay. The SMS assay was performed using 50 μg of protein. The substrate was prepared as a mixture of 40 μM NBD-C 6 -ceramide and 200 μM PC resuspended in 100 mM Tris/HCl (pH 7.4), 50 mM KCl and 1 mM EDTA by sonication and vortexing until clear. For the experiments in which NBD-C 6 -or NBD-C 12 -PC were used, the substrate was prepared as a mixture of 40 μM C 6 -ceramide, 100 μM NBD-PC and 100 μM natural PC. The substrate was diluted 1:1 with the proteins resuspended in lysis buffer (final incubation volume of 100 μl), and the incubation was carried out for 30 min in the dark at 30
• C. The reaction was stopped on ice by addition of 3 vol. of chloroform/methanol (1:1, v/v). After vortexing, the phases were clarified by centrifugation at 2400 g for 5 min. The lower phase was transferred to new tubes, dried down, and lipids were resuspended with 40 μl of chloroform/methanol (2:1, v/v) and separated by TLC in chloroform/methanol/15 mM CaCl 2 (90:52.5:12, by vol.). Fluorescence was measured using a Storm 860 Imaging Analysis System from Amersham Biosciences (U.K.). Results were analysed using ImageQuant software from Amersham Biosciences.
Overexpression of FLAG-SMSs or SMS2-V5
HeLa cells were plated using 0.3 × 10 6 cells per 10-cmdiameter dish. After 2 days, cells were transfected with 1 μg of pcDNA3.1 containing a FLAG-tagged version of SMS1 or SMS2 at the N-terminus (FLAG-SMS1 or FLAG-SMS2) or SMS2 with V5 tag at the C-terminus by the Effectene ® transfection reagent from Qiagen according to the manufacturer's instructions. The constructs were obtained by PCR of full-length cDNA clones purchased from Open Biosystems (Alabama), for FLAG-SMS1 the 5 -primer CAATAAGCTTGCCACCATGGATTAC-AAGGATGACGACGATAAGAAGGAAGTGGTTTATTGGTC-AC and the 3 -primer CACGAATTCTTATGTGTCATTCA-CCAGCCGGCTG was used; for FLAG-SMS2 the 5 -primer CAATAAGCTTGCCACCATGGATTACAAGGATGACG-ACGATAAGGATATCATAGAGACAGCAAAAC and 3 -primer CACGAATTCTCAGGTCGATTTCTCATTGTCTTCAC was used; for SMS2-V5 the 5 -primer CAATAAGCTTGCCACC-ATGGATATCATAGAGACAGCAAAACTTG and the 3 -primer CACGAATTCTCACGTAGAATCGAGACCGAGGAGAGGG-TTAGGGATAGGCTTACCGGTCGATTTCTCATTGTCTTCAC was used.
Cellular metabolism of NBD-C 6 -ceramide
HeLa cells were plated in 10-cm-diameter dishes at a density of either 0.2 × 10 6 or at 0.3 × 10 6 for silencing RNA or overexpression of FLAG-SMS1 and FLAG-SMS2 respectively. After 48 h and 72 h of siRNA treatment or 36 h of overexpression, cells were treated in fresh medium with 5 μM NBD-C 6 -ceramide for up to 8 h. Cells were scraped in 2 ml of ice-cold PBS, and each plate was washed with an additional 2 ml of PBS. Cells and washes were combined and centrifuged for 5 min at 1000 g (4 • C). Lipids were extracted from cell pellets as using the method of Bligh and Dyer [24] . The organic phase was separated into two aliquots of 300 μl for lipid phosphorus determination and 1 ml for lipid analysis. The organic phase for lipid analysis was dried down, and lipids were resuspended with 50 μl of chloroform/methanol (2:1, v/v) and then separated by TLC in chloroform/methanol/15 mM CaCl 2 (90:52.5:12, by vol.). Fluorescence was measured using a Storm 860 Imaging Analysis System from Amersham Biosciences and quantified using ImageQuant. Untreated transfected cells were also collected as control for the expression of FLAG-SMS1 or FLAG-SMS2 by Western blot and for SMS activity.
bSMase (bacterial SMase) treatment and SM re-synthesis
HeLa cells were plated in 10-cm-diameter dishes at a density of 0.3 × 10 6 for overexpression of FLAG-SMS1 or FLAG-SMS2. After 24 h of overexpression, cells were washed with growth medium and then treated with 50 mU/ml bSMase for 60 min. The medium was then removed and cells were washed three times with PBS. After addition of fresh growth medium, the cells were incubated for the indicated time. Cells were then collected and non-radioactive measurement of SM mass levels was performed as previously described [6] . The expression of FLAG-SMS1 and FLAG-SMS2 was confirmed by SMS in vitro activity for each experiment.
Immunofluorescence and confocal microscopy
HeLa cells were plated in 35-mm-diameter confocal dishes at a density of 5 × 10 4 . After 24 h, cells were transfected with 1 μg of pcDNA3.1 plasmid carrying a conventional C1 domain mutated to increase its binding affinity for DAG (YFP-DBD; yellow fluorescent protein-DAG-binding domain) provided by Dr Alexandra Newton (University of California, San Diego, CA, U.S.A.) [25] . After 22 h of transfection, the medium was replaced and cells were treated with 20 nM PMA for 30 min, 10 μM DiC8 (1,2-dioctanoyl-sn-glycerol) for 1 h, 3 μM D-e-C 6 -ceramide or L-e-C 6 -ceramide (where e is erythro) for 1 h in growth medium. For down-regulation of SMSs, cells were plated at a density of 3 × 10 4 in 35-mm-diameter confocal dishes. After 24 h, cells were treated with 10 nM siRNA or Oligofectamine TM alone (control). After 48 h, cells were transfected with 1 μg of YFP-DBD plasmid as described above and incubated for 22 h. In some experiments, 1 μg of PKD-RFP (PKD-red fluorescent protein), provided by Dr O. Rey and Dr E. Rozengurt (David Geffen School of Medicine, University of California, Los Angeles, CA, U.S.A.) was transfected instead for 16 h using Superfect reagent from Qiagen according to the manufacturer's instructions. Cells were then treated as required. In the case of bSMase treatment, 50 mU/ml bSMase was incubated with the cells for 1 h, then bSMase was washed off, and cells were incubated with regular growth medium for an additional 3 h. Treatments were stopped by fixation with 3.7 % formaldehyde for 15 min at room temperature (24 • C). After washing the plates with PBS, the cells were analysed by confocal microscopy. Confocal images were captured and processed using an LSM 510 META laser-scanning microscope (Zeiss, Jena, Germany). In some experiments, HeLa cells were cotransfected with 1 μg each of YFP-DBD and pcDNA 3.1 (empty vector), SMS1-FLAG or SMS2-V5 for 22 h and then treated with 3 μM C 6 -ceramide. After fixation with 3.7 % formaldehyde for 15 min at room temperature, cells were permeabilized with 100 % methanol (−20
• C) for 5 min. Cells were washed three times with 1.5 % FBS in PBS for 5 min each and then blocked in 2.5 % FBS for 1 h at room temperature. Incubation with the primary antibody was performed using mouse monoclonal anti-V5 or anti-FLAG antibodies (from Invitrogen and Sigma respectively) in 1.5 % FBS in PBS with 0. 5 % saponin at 1:100 dilution for 1.5 h at room temperature. Cells were then washed three additional times with 1.5 % FBS/PBS for 5 min each and incubated with anti-mouse Alexa Fluor ® 633-conjugated antibodies (1:400 in 1.5 % FBS in PBS with 0.5 % saponin) for 1 h at room temperature in the dark. Cells were washed three additional times with 1.5 % FBS/PBS for 5 min each before analysis at the confocal microscope. In some experiments, giantin and TGN38 (trans-Golgi network protein 38) were used as Golgi markers. Anti-giantin antibodies from Covant were used at 1:200 dilution, whereas anti-TGN38 antibodies from Santa Cruz were used at 1:50 dilution. Alexa Fluor ® 633-or 488-conjugated anti-rabbit or anti-goat antibodies were used as secondary antibodies. In the experiments with SV40-transformed WI38 cells, 0.025 × 10 6 cells were plated in uncoated confocal dishes. After 48 h, cells were treated with 50 nM siRNA. After 48 h of down-regulation, cells were transfected with 1 μg of YFP-DBD using Effectene ® reagent from Qiagen according to the manufacturer's instructions. After 16 h, cells were treated with 3 μM C 6 -ceramide and then processed accordingly.
YFP-DBD fractionation
HeLa cells were plated in 10-cm-diameter dishes at a density of 0.2 × 10 6 , with four plates for each treatment group. After 48 h, cells were transfected with 0.2-0.5 μg of the mammalian expression plasmid carrying YFP-DBD. After 16 h, cells were treated with 3 μM C 6 -ceramide for 1 h and then collected by scraping in PBS. Cells were lysed by sonication (three cycles of 15 s with 30 s intervals in between). An aliquot was used for detection of total YFP-DBD and the rest was spun at 1000 g for 10 min to separate nuclei. Post-nuclear lysate was centrifuged at 100 000 g for 1 h at 4
• C. Total membrane fractions were resuspended in sample buffer and used for Western blotting. Aliquots of total lysate from each sample with approximately the same level of transfected YFP-DBD were loaded on an SDS/10 % PAGE gel. Aliquots of total membranes corresponding to the fraction of total lysate used were loaded alongside. Gels were transferred on to nitrocellulose membranes which were then blotted with anti-GFP/YFP monoclonal antibodies (Clontech; 1:1000 dilution). The signal was detected after blotting the membranes with HRP (horseradish peroxidase)-conjugated antimouse secondary antibodies (1:6000) and developed by ECL ® (enhanced chemiluminescence) (Amersham). The intensity of the signal was determined by densitometry using Labworks software.
Statistical analysis
Statistical analysis of the data was performed using Student's t-test, and P < 0.05 was considered statistically significant.
RESULTS
Effectiveness and specificity of modulation of SMS1 or SMS2
In order to characterize the role of human SMS1 and SMS2 in the formation of DAG, lipid analysis was conducted upon modulation of the two enzymes by down-or up-regulation of their expressions by transiently transfecting cells with siRNA or SMS expression plasmids. Because this study was initiated prior to the publication of other recent studies in which siRNA was also used [22, 23] , this resulted in different siRNA sequences being used in the present study from the published ones. Therefore a thorough analysis of their effectiveness and specificity was carried out. As illustrated in the Supplementary material section (at http://www.BiochemJ.org/bj/414/bj4140031add.htm) in Supplementary Figure S1 , both siRNA sequences were effective and specific in down-regulating each SMS. Downregulation or up-regulation of SMS1 or SMS2 reduced or enhanced de novo synthesis of SM (Supplementary Figure S2) , and SM mass levels (Supplementary Figure S3) respectively. Down-regulation of either SMS resulted in increased ceramide levels (Supplementary Figure S4 ). These results demonstrate the effectiveness and specificity of the experimental model used in this study to modulate SMS expression. 
Down-regulation of SMS1 or SMS2 does not affect total basal DAG levels
Studies conducted in mammalian cells by us (Supplementary material) and others [7, 18, [20] [21] [22] [23] have confirmed the ability of both SMSs to regulate the levels of SM and ceramide in cells.
On the other hand, no published clear evidence for involvement of SMS1 or SMS2 in the regulation of DAG exists. Therefore it was investigated if down-regulation of SMS1 or SMS2 could also affect the endogenous levels of this bioactive lipid. Interestingly, as shown in Figure 1 (A), down-regulation of neither SMS1 nor SMS2 caused significant changes in total DAG levels as measured by the DGK assay.
SMS1 and SMS2 produce DAG in vitro
Since no significant changes in the basal levels of both PC (putative substrate) and DAG (putative product) were observed upon down-regulation of either SMS, the ability of the two SMSs to use PC as substrate to form DAG, after their expression in mammalian cells, was determined in vitro. After 24 h of overexpression, both FLAG-SMSs were able to produce NBD-C 6 -( Figure 1B ) or NBD-C 12 -DAG ( Figure 1C ) from NBD-C 6 -or NBD-C 12 -PC respectively with an activity profile similar to the one obtained using NBD-C 6 -ceramide as substrate (Supplementary Figure S1D ). These results confirm the ability of SMS1 and SMS2 to form DAG from PC, at least in an in vitro setting.
SMS1 and SMS2 are able to regulate formation of DAG
Because no changes of total DAG levels were observed under basal conditions upon SMSs down-regulation ( Figure 1A ), whereas both SMSs could use PC as substrate to form DAG in vitro ( Figures 1B and 1C ), the possibility that SMSs could modulate subcellular pools of DAG once acute activation of the enzymes is triggered was investigated. μM NBD-C 6 -ceramide for 4 h, and total lipids were extracted as described by Bligh and Dyer [24] ; equal amount of total phospholipids were loaded on to a TLC plate and lipids were separated in chloroform/methanol/15mM CaCl 2 (60:35:8, by vol.). Fluorescent lipids were visualized using a phosphorimager and identified using authentic standards. The results are the means for at least three independent experiments, and error bars represent S.D. and * P < 0.05 compared with Oligofectamine TM alone (A) or vector control (B).
To address this point, YFP-DBD was used to probe subcellular pools of DAG in the cells [25] . Stimulation of SM synthesis was first induced by treatment with short-chain ceramide analogues which have been widely used as a substrate for studying SM synthesis in cells [15, 26] . In order to verify that both SMS1 and SMS2 use these ceramide analogues as substrates once they enter the cells, HeLa cells were treated with NBD-C 6 -ceramide after modulation of SMSs (Figure 2 ). After SMS1 and SMS2 down-regulation (10 nM SMS1 or SMS2 siRNA for 48 h), HeLa cells were treated with 5 μM NBD-C 6 -ceramide for 4 h, and the effect of down-regulation of SMSs on the conversion of NBD-C 6 -ceramide into NBD-C 6 -SM was determined. As shown in Figure 2 (A), down-regulation of SMS1 (SMS1−) or SMS2 (SMS2−) induced a significant decrease in the amount of NBD-C 6 -SM produced by approx. 70 and 40 % respectively. Importantly, no decrease in the production of NBD-C 6 -glucosylceramide was observed (results not shown), supporting, also in this case, the specificity of the effects elicited by the selected SMS1 and SMS2 siRNA. Similar results were obtained at 2, 6 and 8 h of NBD-C 6 -ceramide incubation (results not shown). On the other hand, 24 h of overexpression of FLAG-SMS1 or FLAG-SMS2 significantly enhanced cellular synthesis of NBD-C 6 -SM from NBD-C 6 -ceramide at 4 h ( Figure 2B) . Interestingly, the enhancement of NBD-C 6 -SM production induced a slight decrease of NBD-C 6 -glucosylceramide production, suggesting possible competition for substrate (the same profile was obtained at 2, 6 and 8 h of treatment as well as after 36 h of overexpression; results not shown). Thus these results demonstrate that short-chain ceramide analogues are used as substrate in cells by both SMSs. Moreover, since NBD-C 6 -ceramide is known to be delivered and metabolized to the Golgi, these data also suggest that the fraction of SMS2 present in this compartment has significant SMS activity.
To ascertain that the YFP-DBD is indeed able to respond to changes in the levels of DAG or DAG analogues in the cell, HeLa cells were transfected with YFP-DBD and then loaded with functional analogues of DAG (PMA or DiC8) [16] . Although control cells showed both a diffuse and perinuclear punctate pattern of the YFP-DBD ( Figure 3A ), cells treated with PMA ( Figure 3B ) showed a clear and expected translocation of the YFP-DBD to the plasma membrane, whereas treatment with DiC8 induced translocation of the YFP-DBD to a juxtanuclear subcellular compartment consistent with the Golgi apparatus ( Figure 3C ). These results clearly show the responsiveness of the YFP-DBD to changes in DAG analogue levels within the cells. Once the system proved to be functional, the localization of the YFP-DBD in conditions of stimulated SM synthesis was addressed. Because of the ability of short-chain ceramide analogues to be recognized as SMS substrates (Figure 2) , induction of SM synthesis in YFP-DBD expressing cells was stimulated by treatment with C 6 -ceramide ( Figure 3D ). In response to such treatment, YFP-DBD co-localized with the Golgi marker giantin ( Figures 3E and 3F) , indicating the translocation of the YFP-DBD in the Golgi, a known subcellular site for SM synthesis. In order to make sure that the translocation of the YFP-DBD to the Golgi in ceramide-treated cells was due to metabolism of ceramide and not to the presence of ceramide itself, cells were treated with L-e-C 6 -ceramide, a stereoisomer that is not metabolized in the cells [26] (Figure 3I ). In this case, no significant difference between control ( Figure 3G ) and L-e-C 6 -ceramide treated cells was observed ( Figure 3I ), suggesting that translocation of YFP-DBD is due to ceramide metabolism in the Golgi. Importantly, the site of YFP-DBD translocation when SM synthesis is stimulated corresponded not only to the Golgi ( Figure 3F ) but also to the site of cellular localization of SMS1 ( Figures 4A-4C ) and, in part, of SMS2 ( Figures 4D-4F ). Al-together these results suggest that SM synthesis, stimulated by metabolism of C 6 -ceramide, induces translocation of YFP-DBD through formation of DAG at the Golgi site where SMSs reside.
In order to investigate whether SMSs were responsible for the translocation of YFP-DBD under conditions of active SM synthesis in the Golgi, the effect of knockdown of SMS1 and Figure 5H ). In order to confirm and quantify the effect of down-regulation of SMS1 and SMS2 on the translocation of YFP-DBD, total membrane fractions were isolated after downregulation of either SMSs, transfection with YFP-DBD and C 6 -ceramide treatment. Total cell extracts and respective total membrane fractions were loaded on an SDS gel and the YFP-DBD levels were determined by Western blotting ( Figure 6A ). As shown in Figure 6 (B), quantification of the levels of YFP-DBD present in the membrane fractions over the total YFP-DBD present in each sample revealed a 4-fold reduction of YFP-DBD in the membrane fraction upon SMS1 down-regulation. Less prominent but still significant was the effect of down-regulation of SMS2. Similar results were also obtained in human SV40-transformed WI38 lung fibroblasts as shown by analysis using the confocal microscope (Figures 7 and 8) . Also in this cell line, in nonstimulated conditions, downregulation of either SMS1 or SMS2 did not significantly alter the diffuse pattern of YFP-DBD within the cell (results not shown), whereas treatment with C6-ceramide enhanced localization of YFP-DBD to the Golgi, as shown by its co-localization with the Golgi markers giantin and TGN38 (Figure 7) . On the other hand, downregulation of SMS1 clearly inhibited the Golgi localization of YFP-DBD induced by stimulation of SM synthesis with C6-ceramide ( Figure 8C ). Similar to HeLa, also in SV40-transformed WI38 cells the effect of downregulation of SMS2 was less pronounced than that observed upon SMS1 knock-down but still appreciable ( Figure 8D ). In order to confirm further these results, two additional specific and effective siRNAs targeting SMS2 [22, 23] were also employed (SMS2.2− and SMS2.3−) ( Figures 8E  and 8F ). Importantly, these additional siRNAs confirmed the results obtained with the original SMS2− sequence ( Figure 8D ). Altogether, these results support the hypothesis that SMS1 and, less pronouncedly, SMS2 are able to modulate DAG formation at the Golgi.
To investigate further the ability of SMS1 or SMS2 to regulate DAG formation using endogenous substrates, stimulation of SM synthesis was triggered by increasing ceramide levels through SM hydrolysis induced by acute treatment with bSMase of intact HeLa cells. As shown in Figures 9(A) and 9(B) , 1 h of treatment with bSMase caused the hydrolysis of approx. 60 % of total SM, and once the bSMase was washed off, the cells resynthesized SM up to approx. 85 % of control levels within 4 h. Overexpression of either SMS1 or SMS2 induced a significant increase of SM resynthesis, allowing more than double the amount of SM to be produced in 2.5 h compared with vector control (approx. 17 nmol of SM/nmol of P i for SMSs compared with 7 nmol of SM/nmol of P i for vector) ( Figure 9C ). These results suggest that both SMS1 and SMS2 contribute to SM synthesis from ceramide produced at the plasma membrane. In order to evaluate whether stimulation of SM synthesis from endogenous ceramide would induce formation of DAG, the localization of YFP-DBD was determined in cells treated with bSMase and allowed to re-synthesize SM for 3 h. As shown in Figures 10(A) and 10(B) , SM synthesis from plasma membrane ceramide induced translocation of YFP-DBD to the Golgi ( Figures 10A and 10B compared with Figures 5A and 5B). Importantly, down-regulation of either SMS1 or SMS2 significantly inhibited the translocation of YFP-DBD, causing a more diffuse localization similar to control cells ( Figures 10C  and 10D compared with Figures 5C and 5D) . Altogether, these results suggest that the bulk of ceramide generated at the plasma membrane is routed to the Golgi for SM resynthesis, that both SMS1 and SMS2 at the Golgi are responsible for SM resynthesis to occur and that both SMS1 and SMS2 are capable of DAG formation at the Golgi using endogenous ceramide.
In order to assess the biological functionality of the production of DAG through SMS1 and SMS2 at the Golgi, the effect of stimulation of SM synthesis on the localization of the DAGbinding protein PKD was determined. Stimulation of SM synthesis was triggered by treatment with C 6 -ceramide and it was found to enhance localization of PKD-RFP to a perinuclear region resembling the Golgi apparatus (compare Figure 11A with Figure 11B or 11E). To confirm the enhanced localization of PKD-RFP to the Golgi upon stimulation of SM synthesis, cells transiently trasfected with PKD-RFP and treated with C 6 -ceramide were stained with the Golgi markers giantin ( Figures 11B-11D ) or TGN38 ( Figures 11E-11G ). Indeed the colocalization of PKD-RFP with the Golgi markers after treatment with C 6 -ceramide suggests the relocalization of PKD-RFP to . After being exposed to 1 h treatment with 50 mU/ml bSMase, cells were washed thoroughly and incubated for up to 6 h in the absence of bSMase. Cells were collected at the indicated time points and lipid analysis was performed for non-radioactive SM measurements as described in the Experimental section. For (C), after overexpression of FLAG-SMS1 or FLAG-SMS2 for 18 h, HeLa cells were treated with 50 mU/ml of bSMase for 1 h followed by 2.5 h of incubation in the absence of bSMase; cells were then rinsed, collected in ice-cold PBS, and lipid analysis was performed for non-radioactive SM measurements as described in the Experimental section. The values are representative of at least 3 independent experiments, and error bars represent S.D. and * P < 0.05 compared with vector control.
the site of SM synthesis. Importantly, down-regulation of SMS1 clearly inhibited localization of PKD-RFP to the Golgi ( Figure 12C compared with 12A and 12B), with PKD-RFP scattered throughout the cell similarly to control cells ( Figure 11A) . Comparable with what was observed in the case of YFP-DBD, the effect of down-regulation of SMS2 with all three different siRNA sequences used ( Figures 12D-12F ) was less prominent than that observed after knockdown of SMS1. Overall, these results support the conclusion that SMS1 and, to a lesser extent, SMS2 are able to produce DAG at the Golgi, and that this DAG is biologically active since it is able to recruit DAG-binding proteins such as PKD to this organelle.
DISCUSSION
In the present study we provide direct evidence that both SMS1 and SMS2 possess the ability of regulating the production of DAG at the Golgi, and that this pool of DAG is biologically active. One of the proposed relevant biochemical features of the SMS class of enzymes is the formation of DAG. This biochemical characteristic would make SMS a potentially important regulator for the cross-talk between sphingolipids and glycerolipids. Interestingly, whereas we show that FLAG-tagged SMSs expressed in mammalian cells use PC to produce DAG in vitro, we find that down-regulation of either SMS did not lower the total cellular mass of DAG as measured by the DGK assay. This observation is in agreement with other recently published results [22, 23] , and it might indicate one of the following possibilities: (i) SMSs recognize a very selective endogenous pool of PC, thus producing a specific pool of DAG measurable only by more discriminating methods of detection such as MS; (ii) the endogenous substrate for SMSs is not PC; (iii) alternative pathways that lead to the formation of DAG promptly compensate for the loss of this lipid mediated by down-regulation of SMSs; this possibility would complement a report describing that no accumulation of DAG from SM synthesis can be observed in certain cell lines because of its back-conversion into PC [27] thus suggesting that, in certain cellular settings, the levels of DAG regulated by SMS are strictly controlled.
On the other hand, the use of the YFP-DBD in combination with treatments that stimulate SM synthesis allowed us to visualize the ability of SMS1 and SMS2 to modulate DAG levels at the Golgi. The responsiveness of this mutated C1 domain to localized elevation of DAG was shown in COS-7 cells in response to UTP treatment [25] . In our system, the YFP-DBD proved extremely useful to probe changes in acute localized production of DAG upon down-regulation of SMS1 or SMS2. The acute stimulation of SM synthesis with either C 6 -ceramide or short-term bSMase treatment was key to the success of this approach since there was no significant difference in DAG distribution under basal conditions when SMS1 and SMS2 were down-regulated. This could be due to the fact that the acute stimulation did not allow other metabolic pathways to compensate at the level of control cells for the loss of DAG due to SMS down-regulation.
The observation that SMSs may regulate DAG at the Golgi implicates them in the regulation of DAG-binding proteins known to respond to DAG metabolism in this compartment through the presence of a C1 domain [28] , such as novel PKCs or PKD [16] . The latter, in particular, was found to translocate to the Golgi in response to sphingolipid synthesis, possibly through the formation of DAG by SMS [16] . Indeed we show that knockdown of SMS1 and, to a lesser extent, of SMS2, while causing a decrease of DAG formation in the Golgi (as visualized through the YFP-DBD), also caused inhibition of the localization of PKD to this compartment. The herein reported ability of SMSs to produce DAG provides the first direct evidence for the link between Golgi-localized SMSs and PKD and thus, ultimately, for the regulation of secretion by SMSs. On the other hand, the translocation of PKD to the Golgi was found to feed back negatively on SM synthesis through inactivation of CERT (ceramide transfer protein), which in turn is critical for PKD activation, demonstrating a very tight connection among SM metabolism, PKD activity and regulation of secretion [29] .
Even though evidence in the present study supports the notion that SMS2 localized at the Golgi exerts significant SMS activity (see effects on de novo synthesis of SM presented in Supplementary Figure S2 and on NBD-C 6 -ceramide metabolism presented in Figure 2 ), we observed a considerably milder role for endogenous SMS2 on production and activity of DAG at the Golgi as compared with SMS1. This difference could be simply be a function of the overall lower activity of SMS2 compared with SMS1 in the Golgi which leads to an insufficient amount of DAG produced or to the possibility that SMS1 and SMS2 have different PC substrate specificity and generate different DAG pools with different biological activities or that the pool of DAG produced by SMS1 is more accessible to DAG-binding proteins in the cytosol.
In conclusion, we have shown that SMS1 and, to a lesser extent, SMS2 possess the ability of regulating the production of DAG at the Golgi, and that this pool of DAG is biologically active. These results open up a series of important questions on the function of SMS1 and SMS2 in the regulation of DAG production in response to specific stimuli, on the endogenous source of the phosphorylcholine headgroup and on the reciprocal regulation of SMS1 compared with SMS2. It is our intention to contribute to finding answers to some of these questions with our ongoing studies.
While this manuscript was under revision, a study confirming that down-regulation of either SMS1 or SMS2 is able to regulate DAG levels was published [30] . The fact that in the cell line used in that manuscript showed downregulation of SMSs determined a difference on total DAG levels whereas HeLa cells did not show such a response, indicate that different cell types react differently to perturbation of DAG metabolism.
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EXPERIMENTAL
Real time RT-PCR
Total RNA was extracted using an RNeasy Mini Kit (Qiagen) following the manufacturer's suggested protocol (including the optional DNase and wash steps). Complementary DNA was synthesized from 1 μg of the total RNA, 1 μl of Oligo(dT) 12−18 Primer (Invitrogen), 1 μl of 10 mM dNTP Mix (PCR Grade) (Invitrogen) and sterile water up to 12 μl, which was then incubated for 5 min at 65 (A-C) SMSs were down-regulated by specific siRNAs. HeLa cells were treated with Oligofectamine TM reagent (CT) or with 10 nM of SMS1 (SMS1−) or SMS2 (SMS2−) siRNA for the indicated times. For (A) and (B), cells were collected at the indicated time points, total RNA was extracted, and RT-PCR was performed using specific primers for SMS1 or SMS2 and β-actin. The RT-PCR results were analysed using Q-Gene ® software which expresses data as the means of normalized expression. For (C), after siRNA treatment, HeLa cells were collected and processed for SMS enzymatic assay as described in the Experimental section. For (D), cells were transfected with 1 μg of DNA of either pcDNA3.1 vector plasmid (Vector), FLAG-SMS1 or FLAG-SMS2. After 24 h of overexpression, cells were collected and processed for SMS enzymatic assay as described in the Experimental section. Results are representative of at least three independent experiments; error bars represent S.D. and * P < 0.05 compared with Oligofectamine TM -treated cells.
Buffer, 2 μl of 0.1 M DTT (dithiothreitol) and 1 μl of RNase Out Ribonuclease Inhibitor (Invitrogen) was added to each sample, mixed well, and incubated for 2 min at 42 • C. Each sample then received 1 μl of SuperScript III RNase H − Reverse Transcriptase (Invitrogen), mixed well, incubated for 50 min at 42
• C, and heatinactivated for 15 min at 70
• C. Real-time PCR was performed using 1 μl of cDNA, 1 μl each of forward and reverse primers from 10 μM stocks, 12.5 μl of Bio-Rad iQ SYBR Green 2 × Supermix and 9.5 μl of sterile water. All reactions were performed in triplicate. The Bio-Rad iCycler parameters were set for one cycle of 3 min at 95
• C, 40 cycles of 10 s at 95 • C and 45 s at 61
• C, one cycle of 1 min at 95 • C, one cycle of 1 min at 61
• C and 78 cycles of 10 s at 61
• C. The results were normalized to an internal control gene, β-actin. The real-time RT-PCR results were analysed using Q-Gene ® software, which expresses data as the means of normalized expression [1] . The mean of normalized expression is directly proportional to the amount of RNA of the target gene (SMS2) relative to the amount of RNA of the reference gene (β-actin). The primers were designed using PerkinElmer Primer Express ® software. Primer sequences were as follows: β-actin, forward: 5 -ATTGGCAATGAGCGGTTCC-3 , reverse: 5 -GGTAGTTTCGTGGATGCCACA-3 ; SMS1, forward: 5 -GCCAGGACTTGATCAACCTAACC-3 , reverse: 5 -CCATTGGCATGGCCGTTCTTG-3 ; SMS2, forward: 5 -TC-ACCCAGTGGCTGTTTCTGA-3 , reverse: 5 -TGCATTCCAG-GCACAGGTAGA-3 .
Pulse labelling with [methyl-3 H]choline
HeLa cells were plated in 10-cm-diameter dishes at a density of either 0.2 × 10 6 or 0.3 × 10 6 for siRNA or overexpression of FLAG-SMS1 and FLAG-SMS2 respectively. After 48 or 72 h of siRNA treatment, fresh medium containing 0.5 μCi/ml [methyl-
3 H]choline chloride was added to the cells for 18 h. In the overexpression experiments, cells were transfected in the presence of 0.5 μCi/ml [ 3 H-methyl]choline chloride. Cells were then scraped in 4 ml of cold PBS, combined with growth medium and centrifuged for 5 min at 1000 g. Lipids were extracted from cell pellets using the method of Bligh and Dyer [2] . From the organic phase, 300 μl was used for lipid phosphorus determination and 1.5 ml for base hydrolysis and SM analysis. Base hydrolysis was performed by addition of 1.5 ml of 0.2 M methanolic KOH followed by 1 h incubation at 37
• C. The reaction was stopped by neutralization with HCl and a second Bligh and Dyer extraction was performed [2] . The organic phase was dried down, lipids were resuspended in chloroform/methanol (2:1, v/v), and SM was separated by TLC in chloroform/methanol/15 mM CaCl 2 (90:52.5:12, by vol.). Non-radiolabelled standards were used as reference to identify the SM spot after exposure to iodine vapours and prior to exposing for autoradiography. Radioactivity associated with SM was determined by scintillation counting and normalized against lipid inorganic phosphate.
Measurement of SM mass by steady-state labelling with [methyl-3 H]choline
HeLa cells were plated in 10-cm-diameter dishes at a density of 0.2 × 10 6 for siRNA treatment. Labelling with 0.5 μCi/ml [methyl-3 H]choline chloride was initiated at the time of silencing and carried out for 48 or 72 h. Lipids were extracted as described above. After autoradiography, radioactivity associated with SM was determined by scintillation counting and normalized against lipid inorganic phosphate. For the overexpression experiments, HeLa cells were plated in 10-cm-diameter dishes at a density of 0.3 × 10 6 and labelled with 0.5 μCi/ml [methyl-3 H]choline chloride. After 24 h, constructs were expressed for 18 or 36 h in the presence of 0.5 μCi/ml [methyl-3 H]choline chloride. Cells were collected and lipid extraction was performed as described above.
Non-radioactive measurement of SM mass levels
HeLa cells were plated in 10-cm-diameter dishes at a density of either 0.2 × 10 6 or 0.3 × 10 6 for siRNA or overexpression of FLAG-SMS1 or FLAG-SMS2 respectively. After 48 and 72 h of siRNA treatment or 18 and 36 h after overexpression, cells were scraped in 4 ml of ice-cold PBS, combined with growth medium and centrifuged for 5 min at 1000 g (4 • C). Lipids were extracted from cell pellets using the method of Bligh and Dyer [2] and processed as previously described [3] . SM levels were determined based on the inorganic phosphate associated with the eluted SM spot and normalized against total lipid inorganic phosphate [4] .
Measurement of ceramide steady-state levels
HeLa cells were plated in 10 cm dishes at 0.2 × 10 6 for siRNA for 48 and 72 h. Cells were labelled 24 h before the end of the indicated time points in fresh medium containing 2 μCi/ml [ 3 H]palmitic acid in DMEM supplemented with 10 % FBS. Cells were then collected and lipid extraction was performed as described above. Dried lipids were re-suspended in chloroform/methanol (2:1, v/v) and separated by TLC using a solvent system containing ethyl acetate/iso-octane/acetic acid (9:5:2, by vol.). Non-radiolabelled standards were used as reference to identify the ceramide spot after exposure to iodine vapours and prior to autoradiography. Radioactivity associated with ceramide was determined by scintillation counting and normalized against lipid phosphate measured as described by Ames and Dubin [4] . 
RESULTS
Effect of modulation of either SMS1 or SMS2 on SM metabolism
Because this study was initiated prior to the publication of other studies recently reported in which siRNA was also used [5, 6] , this resulted in different siRNA sequences being used in the present study from the published ones. Therefore a thorough study of their effectiveness and specificity was necessary. After studying their dose-and time-dependent effects on SMS1 or SMS2 expression, it was determined that treatment of HeLa cells with 10 nM SMS1 or SMS2 siRNA for 48 h induced maximal decrease of SMS expression by 95 % for SMS1 and 80 % for SMS2 compared with the Oligofectamine TM -treated mock control as measured by real-time PCR (Figures S1A and S1B) . Importantly, as shown in Figures S1(A) and S1(B), each siRNA sequence reduced only the expression of the targeted SMS, showing specificity of action.
Parallel to the decrease of their expressions, treatment with 10 nM SMS1 or SMS2 siRNA for 48 h induced a significant reduction of SMS activity that reached its maximum after 72 h (average decrease of approx. 60 and 40 % for SMS1 and SMS2 siRNA respectively) ( Figure S1C ). These results are in agreement with those reported by Tafesse et al. [5] and Li et al. [6] . The inhibition of both mRNA and activity was maximal at these incubation times and concentrations; treatment for a shorter time (24 h) or at reduced concentration (5 nM) showed minor or inconsistent results on mRNA levels (results not shown). Co-treatment with siRNA sequences for SMS1 and SMS2 was attempted but, as also observed in other cases of co-silencing, the efficacy of one siRNA sequence (SMS2 in our case) was greatly reduced, and the effect of co-treatment on total SMS activity was similar to that obtained upon treatment with SMS1 siRNA alone. The loss of the efficacy of SMS2 siRNA could not be overcome by increasing its concentrations, thus co-treatment was not included as experimental condition since the results from it would have been misleading.
Up-regulation of SMSs was obtained by overexpression of FLAG-tagged proteins. Transfection for 24 h with FLAG-SMS1 or FLAG-SMS2 led to an increase of total in vitro SMS activity of approx. 3-5-fold for FLAG-SMS1 and 6-11-fold for FLAG-SMS2 (Figures S1D). Similar results were obtained using constructs carrying the FLAG tag at the C-terminus (results not shown) or a V5 tag, suggesting that the presence of the tag at either end of the protein does not have a significant effect on the enzymatic activity.
To verify that the treatment with the selected siRNA exerted an effect on SM metabolism consistent with that reported in the literature [5, 6] , the effect of SMS1 or SMS2 knockdown was evaluated on SM de novo synthesis by cellular pulse labelling with the SM precursor, choline. As shown in Figure S2 (A), after 48 h of SMS1 and SMS2 down-regulation, a decrease in SM synthesis of 80 % and 35 % respectively was already observed. As also shown in Figure S2 (A), similar results were obtained after 72 h of down-regulation. On the other hand, overexpression of FLAG-SMS1 or FLAG-SMS2 for 18 and 36 h resulted in a 30-40 % increase of newly synthesized SM for SMS1, with an increase of 50-60 % for SMS2 ( Figure S2B ). HeLa cells were treated for SMS1 (SMS1−) and SMS2 (SMS2−) down-regulation with 10 nM siRNA for 48 and 72 h. A day before (24 h) the end of the indicated time points, cells were labelled with 2 μCi/ml [ 3 H]palmitic acid. Cells were then collected and lipid extraction was performed using the method of Bligh and Dyer [2] . Ceramide was separated by TLC using ethyl acetate/iso-octane/acetic acid (9:5:2, by vol.). Ceramide quantification was performed as described in the Experimental section. The results shown are representative of three independent experiments. Error bars represent S.D. and * P < 0.05 compared with Oligofectamine-only treated cells (CT).
Next, the effect of modulation of SMS1 or SMS2 activities on SM mass levels was determined. SM mass was determined by both steady-state labelling with the radioactive precursor choline and by non-radioactive measurements. As shown in Figure S3 (A), siRNA treatment targeting either enzyme already caused a modest but significant decrease of SM levels after 48 h (35 % for SMS1 and 20 % for SMS2) with more pronounced effects observed after 72 h of treatment (45 % decrease for SMS1 and 30 % for SMS2). On the other hand, 18 and 36 h of overexpression of FLAG-SMS1 or FLAG-SMS2 increased SM levels ( Figure S3B ). The increase in SM levels was already apparent after 18 h of overexpression (approx. 5-10 %) and it was more pronounced after 36 h of overexpression (20-40 %) . Similar results were observed by measuring SM mass levels through direct isolation of non-radioactive SM with TLC ( Figures S3C and S3D ). In contrast, phosphatidylcholine levels were not significantly affected by modulation of SMSs (307 + − 51 in Oligofectamine TM -treated cells compared with 290 + − 35 and 310 + − 45 in SMS1− and SMS2− cells respectively).
Since down-regulation of both SMS1 and SMS2 caused a significant decrease of SM levels, changes in ceramide levels were also determined, since ceramide serves as a substrate for the reaction. To this end, HeLa cells were labelled with [ 3 H]palmitic acid during down-regulation of SMS1 or SMS2. Radioactive ceramide was then extracted using the method of Bligh and Dyer [2] and isolated by TLC as indicated in the Experimental section. As shown in Figure S4 , after 48 h of down-regulation of both SMS1 and SMS2, there was a tendency to accumulate ceramide as compared with control cells, and this tendency became significant after 72 h of down regulation of either enzyme.
Taken together, these results validate the effectiveness of the selected siRNAs since they affect SM and ceramide levels in a way that is expected for down-regulation of SMSs and the obtained results are similar to those reported by others using different siRNAs. Moreover, these results also demonstrate that up-regulation of either SMS1 or SMS2 affects SM metabolism in cells.
